MarketCap
Lineage Cell Therapeutics LCTX
$ 1.02
4.08%
Facebook
X
Telegram
Lineage Cell Therapeutics Cash Conversion Cycle | LCTX
Annual Cash Conversion Cycle Lineage Cell Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 19.2 | -1.74 K | -1.19 K | 3.37 K | 7.12 K | -2.47 K | 336 | -2.58 K | -1.72 K | -1.55 K | -837 | -787 | -1.71 K | -935 | - | 299 | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 7.12 K | -2.58 K | -291 |
Quarterly Cash Conversion Cycle Lineage Cell Therapeutics
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 4.75 | 7.74 | -3.99 K | - | -4.78 K | -4.76 K | -1.96 K | - | -1.22 K | -1.86 K | -2.06 K | - | -1.04 K | -1.17 K | -1.24 K | 2.06 K | -243 | -2.01 K | -2.17 K | 62.2 | -2.32 K | -3.18 K | -2.44 K | 1.62 | -1.94 K | -2.07 K | -3.21 K | 3.07 | -6.15 K | -2.03 K | -1.37 K | 6.71 | -1.65 K | -17.1 K | -1.99 K | 14.2 | -2.51 K | -1.53 K | -874 | 49.5 | -508 | -851 | -741 | 30.1 | -760 | -690 | -1.78 K | 31.5 | -1.56 K | -1.83 K | -1.13 K | 33.8 | -562 | -1.18 K | -4.85 K | 19.7 | -5.23 K | -1.85 K | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.06 K | -17.1 K | -1.82 K |
Cash Conversion Cycle of other stocks in the Biotechnology industry
| Issuer | Cash Conversion Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Институт стволовых клеток человека
ISKJ
|
104 | - | - | - |  Russia |
 |
Brickell Biotech
BBI
|
26 | - | -5.38 % | $ 6.06 M |  USA |
 |
Generation Bio Co.
GBIO
|
47.6 | - | - | $ 344 M | USA |
 |
Clearside Biomedical
CLSD
|
-4.37 K | - | - | $ 25.3 M | USA |
 |
Merus N.V.
MRUS
|
18.6 | - | - | $ 5.78 B |  Niderland |
 |
AbbVie
ABBV
|
284 | $ 291.22 | 1.06 % | $ 515 B | USA |
 |
22nd Century Group
XXII
|
108 | $ 1.56 | -19.17 % | $ 287 K | USA |
 |
Axon Enterprise
AXON
|
64.5 | $ 313.68 | -18.01 % | $ 24.5 B | USA |
 |
Biogen
BIIB
|
337 | $ 248.51 | 1.88 % | $ 36.4 B | USA |
 |
Theratechnologies
THTX
|
178 | - | - | $ 83.9 M |  Canada |
 |
Exelixis
EXEL
|
-8.32 | $ 69.55 | 1.22 % | $ 18.9 B | USA |
 |
Gilead Sciences
GILD
|
115 | $ 166.9 | -0.4 % | $ 208 B | USA |
 |
Grifols, S.A.
GRFS
|
0.000171 | $ 8.46 | -0.12 % | $ 5.75 B |  Spain |
 |
Alnylam Pharmaceuticals
ALNY
|
31.7 | $ 155.97 | -0.44 % | $ 20.4 B | USA |
 |
Insmed Incorporated
INSM
|
173 | $ 114.55 | 5.32 % | $ 22.8 B | USA |
 |
Johnson & Johnson
JNJ
|
88.2 | $ 274.89 | 0.95 % | $ 662 B | USA |
 |
Titan Pharmaceuticals
TTNP
|
81.3 | - | -3.76 % | $ 3.47 M | USA |
 |
Longeveron
LGVN
|
-212 | $ 1.82 | 6.43 % | $ 32 B | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
-4.27 K | $ 84.95 | 0.13 % | $ 7.99 B | USA |
 |
Mesoblast Limited
MESO
|
0.01 | $ 14.26 | 1.13 % | $ 17.2 B |  Australia |
 |
Adaptimmune Therapeutics plc
ADAP
|
-24.8 K | - | -15.15 % | $ 60.3 M |  Britain |
 |
AVEO Pharmaceuticals
AVEO
|
-284 | - | - | $ 521 M | USA |
 |
Codexis
CDXS
|
-15.2 | $ 1.09 | 6.37 % | $ 95 M | USA |
 |
MannKind Corporation
MNKD
|
349 | $ 3.91 | 4.0 % | $ 1.2 B | USA |
 |
Merck & Co.
MRK
|
110 | $ 146.81 | -0.07 % | $ 367 B | USA |
 |
Dynavax Technologies Corporation
DVAX
|
459 | - | - | $ 2.02 B | USA |
 |
Curis
CRIS
|
64.7 | $ 0.88 | 3.67 % | $ 11.6 M | USA |